Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Jul 28, 2014; 6(7): 480-485
Published online Jul 28, 2014. doi: 10.4329/wjr.v6.i7.480
Published online Jul 28, 2014. doi: 10.4329/wjr.v6.i7.480
Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters
Hinrich A Wieder, Department of Radiology, Zentrum für Radiologie und Nuklearmedizin, 41515 Grevenbroich, Germany
Hinrich A Wieder, Department of Nuclear Medicine, Technische Universität München, 81675 Munich, Germany
Michael Lassmann, Ken Herrmann, Department of Nuclear Medicine, University of Würzburg, 97080 Würzburg, Germany
Martin S Allen-Auerbach, Johannes Czernin, Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, United States
Author contributions: Wieder HA, Lassmann M, Allen-Auerbach M, Czernin J and Herrmann K contributed to development of outline, and revision and approval of manuscript; Wieder HA, Czernin J and Herrmann K contributed to drafting and editing of manuscript; Lassmann M and Allen-Auerbach M contributed to figures.
Correspondence to: Hinrich A Wieder, MD, Department of Radiology, Zentrum für Radiologie und Nuklearmedizin, Zentrum für Radiologie und Nuklearmedizin, Von-Werth-Straße 5, 41515 Grevenbroich, Germany. h@wieder.de
Telephone: +49-2133-664980 Fax: +49-2133-662983
Received: November 27, 2013
Revised: March 20, 2014
Accepted: May 16, 2014
Published online: July 28, 2014
Processing time: 246 Days and 11.1 Hours
Revised: March 20, 2014
Accepted: May 16, 2014
Published online: July 28, 2014
Processing time: 246 Days and 11.1 Hours
Core Tip
Core tip: The incidence rate of prostate cancer worldwide is high. Ninety percent of patients dying of prostate cancer have bone metastases with varying symptoms which are significantly impairing their quality of life. 223Radium is the first therapeutic that results in a survival benefit for patients with bone metastatic, castrate resistant prostate cancer. 223Radium was also associated with low myelosuppression rates and fewer adverse events.This article provides an overview of the pre-clinical and clinical trials with 223Radium.